Global epoprostenol market is expected to grow at a CAGR of 3.0% to 2027Published Date: April 17, 2021 |
As per the latest statistics provided by the National Organization for Rare Diseases (NORD) pulmonary arterial hypertension has a global prevalence rate of 1 – 2 person per 1 million individuals worldwide. It occurs 3 to 5 times more in the female population as compared to male and approximately 15 to 20% of the patient suffering with pulmonary arterial hypertension (PAH) have heritable form of PAH with mutation observed in the BMPR2 gene.
Browse the full report Epoprostenol Market – Growth, Future Prospects, Competitive Analysis, 2020 – 2027 report at https://www.researchcorridor.com/epoprostenol-market/
In the present scenario primary pulmonary hypertension is spearheading the clinical application segment for epoprostenol market. It is considered as a rare progressive disease which is characterized by the occurrence of high blood pressure in the lung arteries with an unknown exact underlying cause. Further clinical investigation has come across chief causative agent which triggers the disease progression are COPD, post-streptococcal rheumatic heart disease, sickle cell disease etc. It is predicted that during the forecast period that patients suffering with NYHA Functional Class III-IV symptoms will be on a rise, hence clinical trial investigation regarding the therapeutic efficacy and safety of epoprostenol in resolving the symptoms will be progressively conducted.
Hospital pharmacy is currently leading the distribution channel segment for the epoprostenol market. Pulmonary edema is the most common side effect associated with drug overdose, hence accurate compounding of epoprostenol by hospital pharmacist is necessary to negate the occurrence of any fatal health outcomes. Retail pharmacy is expected to register comfortable market growth in the near future owing to the flourishing generic drugs market in the developing regions and its ability to provide medication at lower price to patients residing in remote locations.
North America is presently ruling in the geography segment for the epoprostenol market. The growing incidence of primary pulmonary hypertension primarily drives the epoprostenol market growth in the region. As per the latest information provided by the Center for Disease Control and Prevention (CDC), it is estimated that 10% of the U.S. population aged above 65 years are suffering with left-sided heart failure. Additionally, domicile of major players such as Actelion, GlaxoSmithKline, Plc,. Sandoz, Inc. etc. further consolidate the market growth in the region. Europe is the second largest regional segment for epoprostenol market. Effective partnership between academic research institute and pharmaceutical giants in understanding the the role of COPD in the development of pulmonary arterial hypertension determines the market growth in the region. Asia Pacific is anticipated to be the fastest growing regional segment during the forecast period owing to the flourishing generic drugs market and effective implementation of treatment guidelines pertaining to the treatment of pulmonary hypertension in the region.
To know more about the study, request a report sample
Pharmaceutical manufacturers actively engaged in the production of epoprostenol are Actelion (Johnson & Johnson), Merck & Co., Inc., ROTEXMEDICA, GlaxoSmithKline, Plc., Sandoz, Inc., Teva Pharmaceutical Industries Ltd., Bayer AG., Gebro Pharma GmbH, Mayne Pharma and Campus Pharma AB.
Key Market Movements:
- Rising prevalence of pulmonary arterial hypertension worldwide
- Constant rise in the number of clinical trial investigation regarding the therapeutic efficacy of epoprostenol in the treatment of NYHA Functional Class III-IV symptoms
- Affordable reimbursement scenario regarding the therapeutic use of epoprostenol will further accentuate the market growth
Contact Person: Mr. Vijendra Singh
Contact Email: email@example.com
- Global chromosome enumeration probes market is expected to grow at a CAGR of 7.1% to 2027
- Global dried aluminium hydroxide gels market is expected to grow at a CAGR of 3.6% to 2027
- Global chloroquine products market is expected to grow at a CAGR of 4.0% to 2027
- Global epoprostenol market is expected to grow at a CAGR of 3.0% to 2027
- Global ganciclovir market is expected to grow at a CAGR of 6.1% to 2027